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ABSTRACT 
Kidney and bladder stones (urinary tract stones) and osteoporosis are prevalent, serious 
conditions for postmenopausal women. Men with kidney stones are at increased risk of 
osteoporosis; however, the relationship of urinary tract stones to osteoporosis in 
postmenopausal women has not been established. The purpose of this study was to 
Au
tho
r M
an
us
cri
pt
determine whether urinary tract stones are an independent risk factor for changes in bone 
mineral density (BMD) and incident fractures in women in the Women’s Health Initiative 
(WHI). Data were obtained from 150,689 women in the Observational Study and Clinical 
Trials of the WHI with information on urinary tract stones status: 9856 of these women 
reported urinary tract stones at baseline and/or incident urinary tract stones during follow-
up. Cox regression models were used to determine the association of urinary tract stones 
with incident fractures and linear mixed models were used to investigate the relationship 
of urinary tract stones with changes in BMD that occurred during WHI. Follow-up was 
over an average of 8 years. Models were adjusted for demographic and clinical factors, 
medication use, and dietary histories. In unadjusted models there was a significant 
association of urinary tract stones with incident total fractures (HR 1.10; 95% CI, 1.04 to 
1.17). However, in covariate adjusted analyses, urinary tract stones were not significantly 
related to changes in BMD at any skeletal site or to incident fractures. In conclusion, 
urinary tract stones in postmenopausal women are not an independent risk factor for 
osteoporosis. © 2015 American Society for Bone and Mineral Research 
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Introduction 
Osteoporosis is a significant public health problem, particularly for women.(1) Urinary 
tract stones are also a major clinical and economic health concern because approximately 
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7% of women will have symptomatic urinary tract stones by the age of 70 years.(2) 
Moreover, data from the 3rd National Health and Nutrition Examination Survey 
(NHANES III) indicate that the prevalence of urinary tract stones has increased 70% in 
the last 15 years, across all ages and race/ethnic groups, particularly in women.(2) In men, 
urinary tract stones are not only a common, painful event, they are also associated with 
osteoporosis.(3–5) In men in the Osteoporotic Fractures in Men (MrOS) study, kidney 
stones were negatively associated with areal bone mineral density (BMD) by dual-energy 
X-ray absorptiometry (DXA)(6) and were among the strongest negative correlates for 
femoral neck trabecular volumetric BMD.(7) However, whether there is an association 
between urinary tract stones and osteoporosis in women remains controversial.(4,8–14) To 
date, there has not been a longitudinal cohort study of the relationship of urinary tract 
stones to osteoporosis including a large sample of multiethnic postmenopausal women 
with BMD measurements at multiple skeletal sites and incident fracture data. 
 Hypothetically, urinary tract stones may be associated with osteoporosis for a 
number of reasons. Hypercalciuria and higher sodium excretion, which occur in many 
patients with urinary tract stones, have in some studies been reported to be a risk factor 
for osteoporosis.(15–19) Diets higher in potassium intake are inversely associated with both 
urinary tract stones and osteoporosis.(20,21) Urinary tract stones and vertebral fractures 
occur frequently in individuals with asymptomatic hyperparathyroidism.(22) 
 Adequate calcium and vitamin D intakes are beneficial for osteoporosis.(23) 
Some,(24,25) but not all,(26) studies suggest that higher calcium intakes may increase the 
risk of urinary tract stones, although this may vary depending on whether the calcium 
consumed is from diet or supplements, with supplements increasing the risk of urinary 
tract stones and high dietary calcium intakes decreasing the risk.(27) Theoretically, 
persons with urinary tract stones might restrict calcium and vitamin D intake to prevent 
further episodes of symptomatic urinary tract stones, and this may contribute to 
osteoporosis. Therefore, it is important to consider calcium and vitamin D intake (and 
type of intake; ie, diet versus supplements) in studies of the relationship of urinary tract 
stones with osteoporosis. 
 The purpose of this study was to determine whether urinary tract stones were an 
independent risk factor for changes in BMD and incident fractures in women in the 
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Women’s Health Initiative (WHI). 
Subjects and Methods 
Design overview/setting and participants 
The WHI included postmenopausal women aged 50 to 79 years recruited between 
October 1, 1993, and December 31, 1998, at 40 clinical centers in the United States. WHI 
had both an observational study (OS) and a series of clinical trials (CTs) enrolling 
161,808 women. The CTs included the hormone therapy (HT) trial, dietary modification 
(DM) trial, and calcium and vitamin D trial (CaD, calcium carbonate 1000 mg every day 
and vitamin D3 400 IU every day).(28) 
 The study population for the association of urinary tract stones with incident 
fractures included all women in the OS and all arms of the clinical trials (CT) from 
enrollment to end of the main study and for whom data were not missing regarding 
urinary tract stones (n = 150,689). A subset analysis was performed of the association of 
urinary tract stones with incident fractures including those with BMD measurements in 
the models (n = 9626). The study population for the BMD measurements included all 
women in the WHI who had a DXA scan performed in the WHI (DXA cohort). BMD 
measurements of the hip, lumbar spine, or whole body were done on 11,437 women; of 
these, 9883 responded to the baseline evaluation question as to whether or not they had 
previously had a kidney or bladder stone. The association of BMD with urinary tract 
stones thus included 9883 women; 486 (4.9%) of these women reported a history of 
urinary tract stones at the baseline visit of the WHI (Fig. 1). 
<Insert Figure 1> 
 All protocols were approved by the institutional review board (IRB) at each 
participating center. The project was declared exempt by the IRB at Georgia Regents 
University. All participants provided written informed consent for their participation in 
the original WHI study. 
Outcome assessments 
Outcomes were assessed by questionnaires collected semiannually through the end of the 
CT and annually in the OS. The original WHI study was conducted between 1993 and 
2005; data for this analysis is restricted to outcomes occurring before 2005. 
Urinary tract stones 
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The presence or absence of urinary tract stones included self-report of kidney or bladder 
stones collected by questionnaires through the end of the main study. A time-dependent 
variable was used in the modeling to only include stones reported before either fracture or 
BMD measurement. 
Fracture ascertainment 
Information regarding self-reported clinical fractures was collected semiannually through 
the end of the CTs and annually when the trial finished; in the OS, these were reported 
annually. Specific fracture sites assessed included: hip, upper leg (not hip), pelvis, 
patella, lower leg or ankle, foot, coccyx, vertebrae, lower arm or wrist (forearm, hand, 
elbow, upper arm or shoulder, or other site, which was specified). All hip fractures were 
centrally adjudicated within WHI using radiographs and medical record data. Other 
fracture outcomes (spine, forearm, any fractures) were centrally adjudicated in the CT 
trials and for OS participants at the BMD sites during the main study. Total fractures 
included all reported clinical fractures other than those of the ribs, sternum, skull or face, 
fingers, toes, and cervical vertebrae. 
 Validity studies of self-report for fractures within the WHI CT have indicated 
high agreements for self-report of hip (78%) and forearm/wrist (81%) fractures, but 
relatively lower agreement for clinical spine fractures (51%).(29) 
BMD measurements 
BMD of the total hip, femoral neck, anterior-posterior lumbar spine, and whole body was 
measured at baseline, years 3, 6, and 9 in participants at three of the 40 clinical centers of 
the WHI (Pittsburgh, PA; Birmingham, AL, and Phoenix/Tucson, AZ) by DXA using a 
Hologic QDR densitometer Model 2000, 2000+ or 4500 Fan-beam technology (Hologic, 
Inc., Waltham, MA, USA). Only measurements on the same side (for hip images) and on 
the same machine (except where calibrated scanner upgrades occurred) were used for this 
analysis. Technologists were trained and certified by the University of California, San 
Francisco, Bone Density Coordinating Center. Standard protocols were used for 
positioning and analysis. Site-specific spine phantoms were used. Calibration phantoms, 
were scanned across instruments and clinical sites with interscanner variability of <1.5% 
for the lumbar spine, <4.8% for the hip, and <1.7% for linearity.(25,30) 
Covariates 
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Current medication use was ascertained by having the participants bring all of their 
medications that they had used for the prior 2 weeks to the baseline visit. Clinic 
interviewers entered each medication name into the WHI database, which assigned drug 
codes using Medispan software (First Databank, Inc., San Bruno, CA, USA). Information 
regarding duration of use, but not dose, of each medication was recorded. In adjusted 
analyses, use of bisphosphonates, calcitonin, oral corticosteroids, anticonvulsants, proton 
pump inhibitors, thiazide diuretics, loop diuretics, and thyroid medications were included. 
Thyroid medications included thyroid replacement therapy for hypothyroidism and 
medications used to treat hyperthyroidism including methimazole and propylthiouracil. 
 The use of dietary supplements, including calcium and vitamin D preparations 
taken at least twice weekly for the prior 2 weeks, were also entered into the database. 
Dietary intakes of potassium, calcium, vitamin D, oxalate, sodium, animal proteins, 
fluid/water, and total caloric intake were measured with a semiquantitative food-
frequency questionnaire (FFQ). As in previous WHI studies, dietary intake values for 
women who reported extremes of caloric intakes were not included in the analysis.(31) 
Dietary energy intake was analyzed categorically as <1800, 1800 to 2199 (referent 
group), 2200 to 2499, and ≥2500 kilocalories per day. These categories were selected 
based on the distribution of energy intake in the women in the WHI-OS cohort, and the 
estimated energy requirements from the Institute of Medicine dietary reference intakes 
for women aged 50 to 79 years with varying levels of physical activity.(32) Questionnaires 
obtained at the baseline visit were used to collect information regarding age, race and 
ethnicity, smoking exposure (current, past, never), alcohol intake, parental history of 
fractures after age 40 years, history of prevalent fractures on or after age 55 years, age at 
menopause, menopausal hormone therapy (estrogen therapy or estrogen + progesterone), 
socioeconomic status including family income (total over prior year), education (less than 
or equal to high school diploma/some college or vocational school/completed college and 
higher), and history of diabetes mellitus. Total energy expenditure from self-reported 
recreational physical activity was used to determine physical activity levels. Physical 
activity was determined by a questionnaire that addressed the frequency, duration, and 
intensity of participation in different forms of physical activity. Weekly recreational 
physical activity and walking per kilogram of body weight was calculated by multiplying 
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an assigned energy expenditure level for each category of activity by the hours exercised 
per week to calculate total metabolic equivalents per week (METs per week).(33,34) The 
Short Form 36 Health Survey (SF-36) was used as a measure of physical function 
construction, with higher scores indicating better function. Height and weight at the 
baseline visit were measured in WHI as described(28); these were used to calculate body 
mass index (BMI). Geographic study site was categorized by region (Northeast, South, 
Midwest, West).(35) Indicators were created for participation in each arm (treatment and 
control) of each clinical trial. 
Statistical analysis 
Selected baseline characteristics of the study population according to the presence or 
absence of urinary tract stones, including prevalent (at baseline visit), incident (developed 
during WHI), and recurrent (prevalent and incident) urinary tract stones were described. 
For each characteristic, we present the number of participants, means and standard 
deviation (SD) for continuous variables and frequencies and percentages for categorical 
variables. 
 Baseline covariates were compared across urinary tract stone groups using 
ANOVA; p values from Tukey-Kramer post hoc pairwise comparisons are reported 
herein. 
 Linear mixed-effects models were used to determine the association of urinary 
tract stones with changes in BMD over time. Repeated observations of BMD and urinary 
tract stones (yes/no) were used to compute the annual change in BMD as a function of 
urinary tract stones status. An F-test was used to test equality of slopes. 
 Cox regression models were used to examine the relationship of urinary tract 
stones with fractures (total [all fractures] and site-specific fractures [hip, clinical 
vertebral, and other fractures]) with time to first fracture as the dependent variable and 
self-report of urinary tract stones as a time-varying independent variable. Women were 
followed to first fracture; women without fracture were censored at the end of follow-up. 
This analysis was repeated in the BMD cohort, where adjustment for BMD was possible. 
 Model covariates were selected a priori based on their associations with 
osteoporosis (age; ethnicity; education; income; study arm; smoking and alcohol use; 
fracture history; physical functioning; age at menopause; BMI; diabetes; dietary calcium; 
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vitamin D, sodium, and potassium intakes; calcium and vitamin D supplements; and use 
of bisphosphonates, oral corticosteroids, calcitonin, estrogen, selective estrogen receptor 
modulators [SERMs], thiazolidinediones, antiepileptics, proton pump inhibitors, thiazide 
and loop diuretics, and thyroid medications) and/or urinary tract stones (age; ethnicity; 
BMI; study arm; dietary calcium; vitamin D, sodium, potassium, oxalic acid, animal 
protein, energy, and fluid intakes; and use of supplemental calcium and vitamin D 
supplements, thiazide diuretics, and allopurinol) and all were entered into the models 
simultaneously. The collinearity of the variables was assessed by variance inflation 
factors. Covariates were obtained from the baseline visit except for urinary tract stones 
where we constructed a time-varying indicator Neph(t) = at least one episode of urinary 
tract stones prior to t. Unadjusted models and models adjusted for all covariates described 
above are presented. Sensitivity analyses were analyzed including women who had a 
constant status of urinary tract stones (ie, never or at baseline already) and also using only 
the portion of longitudinal data for each woman during which urinary tract stones status 
did not change. In a subset analysis of the association of urinary tract stones with incident 
fractures who had DXA measurements (n = 9626), baseline lumbar spine and hip BMD 
were used as covariates in adjusted analyses. Finally, sensitivity analyses of the 
association of urinary tract stones with changes in BMD and fractures confined to women 
in the OS were done; this analysis was performed to mitigate any biases from trial 
assignment and arm assignment (placebo versus treatment) that might have still been a 
factor, despite statistical adjustment for CT trial and trial assignment in women in the 
CTs of the WHI included in the primary analyses. 
 All analyses were done using SAS version 9.3 (SAS Institute, Inc., Cary, NC, 
USA). 
Results 
Characteristics of women with and without a history of urinary tract stones fractures 
including those with baseline (prevalent urinary tract stones), incident (during study), 
recurrent (prevalent and incident urinary tract stones) are shown in Supporting Table 1. A 
total of 9856 women reported having urinary tract stones at baseline or during follow-up. 
Overall, 5993 women (4%) had a prevalent stone reported at the baseline visit; of those, 
5259 women (3.5%) had stones only at baseline and 734 women (14%) had another stone 
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during WHI follow-up (recurrent). An initial stone during follow-up without prior history 
occurred in 3863 women (2.6%). Women were followed for an average of 8 years. 
Differences in demographic and clinical characteristics by history of urinary tract stones 
were similar to those recently reported from women in the WHI OS.(36) In women with 
urinary tract stones, in particular for those with recurrent stones, there were higher dietary 
intakes of energy (p < 0.001), animal protein (p = 0.002), and sodium (p < 0.001), and 
relatively lower intakes of potassium (p = 0.042), fluid/water (p = 0.002), oxalic acid (p = 
0.009), calcium (p = 0.309), and vitamin D (p = 0.986) reported than in non–stone-
formers. There were no significant differences in calcium (p = 0.309) or vitamin D (p = 
0.986) in women with urinary tract stones compared to those without. 
 In unadjusted and adjusted models, respectively, there was no significant 
association of urinary tract stones with changes in BMD at the total hip (p = 0.57 and p = 
0.33), femoral neck (p = 0.50 and p = 0.49), lumbar spine (p = 0.13 and p = 0.38), or 
whole body (p = 0.15 and p = 0.38). In sensitivity analyses including women who had a 
constant status of urinary tract stones (never or at baseline already) there was no 
significant association of urinary tract stones with changes in BMD in unadjusted and 
adjusted models, respectively, for the skeletal sites of the total hip (p = 0.91 and p = 
0.49), femoral neck (p = 0.99 and p = 0.96), lumbar spine (p = 0.13 and p = 0.38), or 
whole body (p = 0.32 and p = 0.75). In sensitivity analysis including only women with 
prevalent urinary tract stones or those who never had urinary tract stones there was no 
significant association of urinary tract stones with changes in BMD at the total hip (p = 
0.91 and p = 0.49), femoral neck (p = 0.99 and p = 0.96), or whole body (p = 0.32 and p 
= 0.75). There was a significant positive association of urinary tract stones with increases 
in BMD at the lumbar spine in unadjusted models (p = 0.03), which disappeared after 
adjustment for covariates (p = 0.17). In sensitivity analysis using only the portion of 
longitudinal data for each woman during which urinary tract stones status did not change, 
there was again no significant association of urinary tract stones with changes in BMD in 
unadjusted and adjusted models, respectively, for the total hip (p = 0.90 and p = 0.48), 
femoral neck (p = 1.00 and p = 0.97), or whole body (p = 0.32 and p = 0.75). There was a 
significant positive association of urinary tract stones with increases in BMD at the 
lumbar spine in unadjusted models (p = 0.02), which disappeared after adjustment for 
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covariates (p = 0.16) (Table 1). 
<Insert Table 1> 
 Incident fractures occurred at any site in 21,762 of 150,689 women over an 
average of 7.6 years of follow-up, for a fracture rate of 19.4 per 1000 person-years. This 
included 20,591 fractures in 141,326 women without urinary tract stones, for a fracture 
rate of 19.3 per 1000 person-years and 1171 incident fractures in 9363 women with 
urinary tract stones preceding the fracture, for a fracture rate of 21.4 per 1000 person-
years. In unadjusted models there was a significant association of urinary tract stones 
with incident total fractures (HR 1.10; 95% CI, 1.04 to 1.17), clinical spine fractures (HR 
1.30; 95% CI, 1.10 to 1.53), and other fracture sites (HR 1.08; 95% CI, 1.01 to 1.15); 
although in a similar direction, these associations were no longer statistically significant 
after covariate adjustment (HR 1.04 [95% CI, 0.97 to 1.12]; HR 1.17 [95% CI, 0.95 to 
1.43]; and HR 1.02 [95% CI, 0.94 to 1.10], respectively) (Table 2). In a subset analysis 
including 9626 women who had BMD measurements there was no significant association 
of urinary tract stones after inclusion of lumbar spine BMD (HR 1.08; 95% CI, 0.87 to 
1.34) or hip BMD (HR 1.08; 95% CI, 0.87 to 1.34) in the models. Sensitivity analyses of 
the association of urinary tract stones with changes in BMD and incident fractures limited 
to only the WHI OS women, revealed similar findings to the whole cohort (data not 
shown). 
<Insert Table 2> 
Discussion 
This is the largest cohort of multiethnic postmenopausal women with urinary tract stones 
(including approximately 10,000 women with kidney/bladder stones) ever examined for 
fracture risk and osteoporosis. The major finding of this report is that, after model 
adjustments, there was no significant association of urinary tract stones with changes in 
BMD at multiple skeletal sites. Fractures, including total fractures and site specific of the 
hip, vertebral fractures, and other fracture sites, were also not significantly associated 
with urinary tract stones in the multivariable model. 
 In longitudinal adjusted analyses there was no association of changes in BMD at 
any site with a history of kidney/bladder stones. These findings are in accord with some 
other smaller studies, which have reported that urinary tract stones are not associated with 
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hip BMD(4,8,11) or lumbar spine BMD.(8,11) In contrast, a recent case-control study from 
Taiwan suggested that there was a positive association between a first time diagnosis of 
osteoporosis by BMD measurements and prior urinary calculus; however, this study 
included both men and women and 98% of participants were of Hans Chinese 
ethnicity.(14) To our knowledge, that in postmenopausal women in WHI, whole-body 
BMD was not related to urinary tract stones, is the first time that the association of 
urinary tract stones with whole-body BMD has been reported. 
 The findings in women in WHI that urinary tract stones were not significantly 
related to incident fractures are in accord with cross-sectional data from women in 
NHANES III.(4) In contrast, one retrospective cohort study that included 181 women 
followed over 25 years suggested that there was an increased standard morbidity ratio 
(compared with population-based expected rates) of vertebral fractures in women with 
urinary tract stones; although, similar to WHI, they found no relationship of morbidity 
ratios for other fracture sites, including the hip, humerus, and forearm, with urinary tract 
stones.(9) More recently, a population-based cohort study using The Health Improvement 
Network (THIN) reported a slightly higher fracture risk in women with urolithiasis 
compared to those without; the risk was greatest in women younger than WHI 
participants, specifically, in those aged 30 to 39 years.(37) In WHI, prior to covariate 
adjustment, risks for fracture in those with urolithiasis were very similar to what was 
reported in THIN, with a 10% increased risk in WHI and a 17% increase in older women 
in THIN.(37) In contrast with THIN, in WHI, the increased risk for fracture was no longer 
present after covariate adjustment. However, in WHI we were able to adjust for a number 
of important covariates that were not included in THIN, including diet, smoking and 
alcohol intake, physical activity, menopausal history, and family history of osteoporosis. 
Additionally, race/ethnicity was not reported in THIN and only a subset had BMI data.(37) 
 Calcium and vitamin D supplementation,(26,27) higher salt intakes,(17–19) higher 
caloric consumption,(38) higher animal protein intake,(39) lower potassium intake,(20,21) and 
lower water consumption(40) are risk factors for stone formation. In WHI, the association 
of urinary tract stones with total, clinical spine, and other fractures in unadjusted models 
disappeared after adjustment for covariates that are associated with osteoporosis and/or 
urinary tract stones; this was prior to adjustment for dietary or supplement intakes. 
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Additionally, the lack of association of urinary tract stones with longitudinal changes in 
BMD was independent of when the stone occurred or how many times a kidney/bladder 
stone occurred. 
 There are a number of limitations to our analysis. To start, this is an observational 
cohort (with respect to the outcomes examined) and data is limited for some covariates, 
in particular for medication use, for which dose was not collected. History of urinary tract 
stones was obtained from self- report only. However, self-report of urinary tract stones is 
very reliable and has been reported to be 97% to 98% accurate.(41) Stone composition was 
not known; however, the authors suspect that only a few of these stones were uric acid 
stones, because less than 1% of women were on allopurinol, which might be used to treat 
uric acid–containing stones.(42) Radiographs or ultrasounds to assess for asymptomatic 
stones or vertebral fractures were not obtained. Biochemical analysis of urine specimens 
for hypercalciuria were not collected, and it is possible that urinary tract stones in the 
subset of women with hypercalciuria might be associated with osteoporosis.(10,11,43) The 
questionnaire used in WHI did not distinguish kidney from bladder stones, although in 
women bladder stones are very rare (<5% of all stones).(44) The three clinical centers that 
participated in the DXA measurements were selected to provide maximum racial and 
ethnic diversity, and thus were not representative of the WHI as a whole.(45) The 
statistical analysis also has limitations. All covariates that were available in WHI and 
associated with osteoporosis and/or urinary tract stones were included and entered 
simultaneously in the model. By adjusting for all these covariates, it is possible that we 
“overadjusted”; ie, adjusted for a potential confounder that could also be a mediator of 
the association of urinary tract stones with osteoporosis. For example, individuals with 
urinary tract stones are frequently prescribed hydrochlorothiazide,(46) which in some 
studies has been associated with higher BMD(47) and fewer fractures.(48) 
 This study had a number of important strengths. To the authors’ knowledge, this 
is the largest, most comprehensive analysis of the association of urinary tract stones with 
incident fractures to date in postmenopausal women. It includes women of all races and 
ethnicities and includes both BMD measurements from multiple sites and fractures from 
multiple locations. 
 In conclusion, urinary tract stones are not an independent risk factor for 
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osteoporosis in postmenopausal women. 
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Fig. 1. Flow diagram of study population. 
 
 
 
Supporting Table 1. Study Population Characteristics by Baseline and Incident Urinary Tract Stone Status 
 
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Age (years)      
Mean (SD) 63.3 (7.2) 63.3 (7.2) 63.6 (7.2) 63.2 (7.2) 63.4 (7.3) 
<60 48,969 (32.5) 45,884 (32.6) 1,628 (31.0) 240 (32.7) 1,217 (31.5) 
60-69 68,035 (45.1) 63,555 (45.1) 2,400 (45.6) 335 (45.6) 1,745 (45.2) 
≥70 33,685 (22.4) 31,394 (22.3) 1,231 (23.4) 159 (21.7) 901 (23.3) 
Ethnicity      
White  124,606 (82.9) 116,612 (83.0) 4,355 (83.0) 575 (78.6) 3,064 (79.7) 
Black  
or African-American 
13,529 (9.0) 12,658 (9.0) 379 (7.2) 67 (9.2) 425 (11.1) 
Hispanic/Latino 5,737 (3.8) 5,223 (3.7) 271 (5.2) 49 (6.7) 194 (5.0) 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Other 6,438 (4.3) 5,992 (4.3) 242 (4.6) 41 (5.6) 163 (4.2) 
Missing 379 348 12 2 17 
Education      
≤High school diploma 33,333 (22.3) 30,764 (22.0) 1,366 (26.2) 222 (30.9) 981 (25.7) 
Some college 
/vocational school  
56,653 (37.9) 52,714 (37.7) 2,118 (40.6) 295 (41.0) 1,526 (40.0) 
College degree or 
higher 
59,552 (39.8) 56,309 (40.3) 1,730 (33.2) 202 (28.1) 1,311 (34.3) 
Missing 1151 1,046 45 15 45 
Family Income        
Less than $19,999 23,200 (16.0) 21,320 (15.8) 979 (19.4) 172 (24.5) 729 (19.7) 
$20,000 to $49,999 62,862 (43.5) 58,673 (43.4) 2,241 (44.4) 290 (41.4) 1,658 (44.8) 
$50,000 or more 58,577 (40.5) 55,190 (40.8) 1,832 (36.3) 239 (34.1) 1,316 (35.5) 
Missing 6050 5,650 207 33 160 
Region      
Northeast 34,235 (22.7) 32,070 (22.8) 1,093 (20.8) 176 (24.0) 896 (23.2) 
Au
tho
r M
an
us
cri
pt
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
South 38,809 (25.8) 36,143 (25.7) 1,415 (26.9) 219 (29.8) 1,032 (26.7) 
Midwest 33,423 (22.2) 31,283 (22.2) 1,123 (21.4) 149 (20.3) 868 (22.5) 
West 44,222 (29.3) 41,337 (29.4) 1,628 (31.0) 190 (25.9) 1,067 (27.6) 
Smoking status      
Never Smoked 75,957 (51.0) 71,010 (51.0) 2,658 (51.2) 368 (50.7) 1,921 (50.4) 
Past Smoker 62,720 (42.1) 58,696 (42.2) 2,149 (41.4) 298 (41.0) 1,577 (41.3) 
Current Smoker 10,195 (6.8) 9,431 (6.8) 388 (7.5) 60 (8.3) 316 (8.3) 
Missing 1817 1,696 64 8 49 
Fracture at Age 55+2      
No 100,874 (71.9) 94,408 (72.0) 3,448 (71.6) 467 (69.2) 2,551 (71.5) 
Yes 19,833 (14.1) 18,434 (14.1) 747 (15.5) 112 (16.6) 540 (15.1) 
Not applicable 
(age<55) 
19,511 (13.9) 18,318 (14.0) 619 (12.9) 96 (14.2) 478 (13.4) 
Missing 10471 9,673 445 59 294 
Parent with 
fracture after 40 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
No 83,932 (60.3) 78,528 (60.3) 2,860 (59.7) 402 (59.6) 2,142 (60.7) 
Yes 55,193 (39.7) 51,605 (39.7) 1,928 (40.3) 273 (40.4) 1,387 (39.3) 
Missing 11564 10,700 471 59 334 
Parent with hip 
fracture after 40 
     
No 99,980 (83.2) 93,513 (83.2) 3,437 (83.2) 477 (83.5) 2,553 (84.3) 
Yes 20,198 (16.8) 18,936 (16.8) 692 (16.8) 94 (16.5) 476 (15.7) 
Missing 30511 28,384 1,130 163 834 
In general, health is      
Excellent 25,627 (17.1) 24,545 (17.5) 572 (10.9) 59 (8.1) 451 (11.8) 
Very good 61,360 (40.9) 57,808 (41.3) 1,933 (36.9) 220 (30.2) 1,399 (36.5) 
Good 49,400 (33.0) 45,756 (32.7) 1,948 (37.2) 293 (40.2) 1,403 (36.6) 
Fair/poor 13,525 (9.0) 12,000 (8.6) 784 (15.0) 157 (21.5) 584 (15.2) 
Missing 777 724 22 5 26 
Physical Functioning 
Construct 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Mean (SD) 81.1 (20.0) 81.4 (19.8) 76.7 (21.8) 71.1 (25.0) 76.7 (22.8) 
Missing 2651 2461 89 12 89 
Alcohol intake      
Non drinker 16,306 (10.9) 14,996 (10.7) 684 (13.1) 131 (18.0) 495 (12.9) 
Past drinker 27,947 (18.7) 25,770 (18.4) 1,148 (22.0) 172 (23.6) 857 (22.4) 
<1 drink per month 18,619 (12.4) 17,312 (12.4) 703 (13.4) 104 (14.3) 500 (13.1) 
<1 drink per week 30,705 (20.5) 28,719 (20.5) 1,066 (20.4) 141 (19.3) 779 (20.4) 
1 to <7 drinks per week 38,469 (25.7) 36,349 (26.0) 1,139 (21.8) 130 (17.8) 851 (22.3) 
7+ drinks per week 17,696 (11.8) 16,815 (12.0) 489 (9.4) 51 (7.0) 341 (8.9) 
Missing 947 872 30 5 40 
CT Participant      
No 90,439 (60.0) 84,618 (60.1) 3,163 (60.1) 419 (57.1) 2,239 (58.0) 
Yes 60,250 (40.0) 56,215 (39.9) 2,096 (39.9) 315 (42.9) 1,624 (42.0) 
BMD study      
No 141,334 (93.8) 132,191 (93.9) 4,871 (92.6) 667 (90.9) 3,605 (93.3) 
Yes 9,355 (6.2) 8,642 (6.1) 388 (7.4) 67 (9.1) 258 (6.7) 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
HTArm      
Not randomized to HT 126,304 (83.8) 118,090 (83.9) 4,411 (83.9) 618 (84.2) 3,185 (82.4) 
E-alone intervention 4,740 (3.1) 4,349 (3.1) 189 (3.6) 31 (4.2) 171 (4.4) 
E-alone control 4,757 (3.2) 4,379 (3.1) 200 (3.8) 33 (4.5) 145 (3.8) 
E+P intervention 7,487 (5.0) 7,028 (5.0) 223 (4.2) 28 (3.8) 208 (5.4) 
E+P control 7,401 (4.9) 6,987 (5.0) 236 (4.5) 24 (3.3) 154 (4.0) 
DM Arm      
Not randomized to DM 107,940 (71.6) 100,919 (71.7) 3,776 (71.8) 495 (67.4) 2,750 (71.2) 
Intervention 17,104 (11.4) 16,002 (11.4) 588 (11.2) 96 (13.1) 418 (10.8) 
Control 25,645 (17.0) 23,912 (17.0) 895 (17.0) 143 (19.5) 695 (18.0) 
CaD Arm      
Not randomized to CaD 118,221 (78.5) 109,449 (77.7) 4,930 (93.7) 720 (98.1) 3,122 (80.8) 
Intervention 16,257 (10.8) 15,680 (11.1) 165 (3.1) 6 (0.8) 406 (10.5) 
Control 16,211 (10.8) 15,704 (11.2) 164 (3.1) 8 (1.1) 335 (8.7) 
BMI (kg/m2)      
Mean (SD) 27.9 (6.0) 27.9 (5.9) 28.9 (6.2) 30.0 (6.4) 29.1 (6.3) 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Underweight (< 18.5) 1,338 (0.9) 1,261 (0.9) 41 (0.8) 9 (1.2) 27 (0.7) 
Normal (18.5 - 24.9) 51,625 (34.6) 48,917 (35.0) 1,503 (28.9) 156 (21.4) 1,049 (27.4) 
Overweight (25.0 - 
29.9) 
51,734 (34.6) 48,359 (34.6) 1,774 (34.1) 243 (33.4) 1,358 (35.4) 
Obesity I (30.0 - 34.9) 27,420 (18.4) 25,348 (18.2) 1,088 (20.9) 181 (24.9) 803 (21.0) 
Obesity II (35.0 - 39.9) 11,182 (7.5) 10,216 (7.3) 504 (9.7) 88 (12.1) 374 (9.8) 
Extreme Obesity III 
(>= 40) 
6,040 (4.0) 5,475 (3.9) 293 (5.6) 51 (7.0) 221 (5.8) 
Missing 1350 1,257 56 6 31 
Dietary Energy (kcal/d)      
Mean (SD) 1638.5 (640.6) 1637.3 (638.4) 1648.4 (659.3) 1730.3 (734.6) 1649.5 (673.7) 
<1800 97,496 (66.7) 91,281 (66.8) 3,338 (65.8) 423 (60.6) 2,454 (65.9) 
1800-2200 24,841 (17.0) 23,249 (17.0) 874 (17.2) 120 (17.2) 598 (16.1) 
2200-2500 10,283 (7.0) 9,584 (7.0) 355 (7.0) 68 (9.7) 276 (7.4) 
≥2500 13,525 (9.3) 12,533 (9.2) 508 (10.0) 87 (12.5) 397 (10.7) 
Missing 4544 4,186 184 36 138 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Dietary Animal Protein 
(g/d) 
     
Mean (SD) 48.0 (23.4) 47.9 (23.4) 47.9 (23.4) 51.1 (28.1) 48.4 (24.9) 
<28 29,229 (20.0) 27,207 (19.9) 1,067 (21.0) 138 (19.8) 817 (21.9) 
28-39 29,229 (20.0) 27,450 (20.1) 968 (19.1) 154 (22.1) 657 (17.6) 
39-49 29,229 (20.0) 27,399 (20.1) 1,011 (19.9) 104 (14.9) 715 (19.2) 
49-64 29,229 (20.0) 27,354 (20.0) 981 (19.3) 127 (18.2) 767 (20.6) 
>64 29,229 (20.0) 27,237 (19.9) 1,048 (20.7) 175 (25.1) 769 (20.6) 
Missing 4544 4,186 184 36 138 
Dietary Potassium 
(mg/d) 
     
Mean (SD) 2628.7 (963.5) 2635.0 (962.6) 2534.1 (961.5) 
2538.7 
(1014.7) 
2542.4 (977.9) 
<1810 29,229 (20.0) 27,001 (19.8) 1,179 (23.2) 173 (24.8) 876 (23.5) 
1810-2290 29,229 (20.0) 27,244 (19.9) 1,064 (21.0) 150 (21.5) 771 (20.7) 
2290-2757 29,229 (20.0) 27,359 (20.0) 1,027 (20.2) 128 (18.3) 715 (19.2) 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
2757-3368 29,229 (20.0) 27,496 (20.1) 892 (17.6) 120 (17.2) 721 (19.4) 
>3368 29,229 (20.0) 27,547 (20.2) 913 (18.0) 127 (18.2) 642 (17.2) 
Missing 4544 4,186 184 36 138 
Dietary Sodium (mg/d)      
Mean (SD) 2742.4 
(1153.5) 
2740.3 
(1150.4) 
2760.2 
(1174.9) 
2914.8 
(1352.1) 
2764.8 
(1192.5) 
<1796 29,229 (20.0) 27,262 (20.0) 1,049 (20.7) 140 (20.1) 778 (20.9) 
1796-2302 29,229 (20.0) 27,442 (20.1) 960 (18.9) 119 (17.0) 708 (19.0) 
2302-2822 29,229 (20.0) 27,396 (20.0) 1,012 (19.9) 130 (18.6) 691 (18.6) 
2822-3552 29,229 (20.0) 27,334 (20.0) 1,003 (19.8) 138 (19.8) 754 (20.2) 
>3552 29,229 (20.0) 27,213 (19.9) 1,051 (20.7) 171 (24.5) 794 (21.3) 
Missing 4544 4,186 184 36 138 
Dietary Oxalic Acid 
(mg/d) 
     
Mean (SD) 312.3 (144.6) 313.1 (144.5) 302.1 (144.2) 295.8 (142.3) 299.7 (145.2) 
<192 29,229 (20.0) 27,004 (19.8) 1,170 (23.1) 151 (21.6) 904 (24.3) 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
192-254 29,229 (20.0) 27,298 (20.0) 1,033 (20.4) 166 (23.8) 732 (19.7) 
254-322 29,229 (20.0) 27,342 (20.0) 1,003 (19.8) 140 (20.1) 744 (20.0) 
322-417 29,229 (20.0) 27,466 (20.1) 944 (18.6) 129 (18.5) 690 (18.5) 
>417 29,229 (20.0) 27,537 (20.2) 925 (18.2) 112 (16.0) 655 (17.6) 
Missing 4544 4,186 184 36 138 
Dietary Fluid/Water 
(g/d)      
Mean (SD) 1578.3 (637.1) 1583.3 (636.8) 1506.7 (628.7) 1497.9 (658.1) 1507.0 (643.4) 
<1049 29,229 (20.0) 26,871 (19.7) 1,245 (24.5) 183 (26.2) 930 (25.0) 
1049-1354 29,229 (20.0) 27,271 (20.0) 1,034 (20.4) 154 (22.1) 770 (20.7) 
1354-1645 29,229 (20.0) 27,409 (20.1) 996 (19.6) 117 (16.8) 707 (19.0) 
1645-2041 29,229 (20.0) 27,482 (20.1) 966 (19.0) 109 (15.6) 672 (18.0) 
>2041 29,229 (20.0) 27,614 (20.2) 834 (16.4) 135 (19.3) 646 (17.3) 
Missing 4544 4,186 184 36 138 
Dietary Calcium (mg/d)      
Mean (SD) 826.8 (450.5) 828.8 (450.2) 796.1 (445.2) 799.3 (476.3) 802.3 (461.2) 
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  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
<459 29,229 (20.0) 27,065 (19.8) 1,137 (22.4) 171 (24.5) 856 (23.0) 
459-639 29,229 (20.0) 27,280 (20.0) 1,084 (21.4) 142 (20.3) 723 (19.4) 
639-838 29,229 (20.0) 27,362 (20.0) 969 (19.1) 141 (20.2) 757 (20.3) 
838-1142 29,229 (20.0) 27,406 (20.1) 973 (19.2) 118 (16.9) 732 (19.7) 
>1142 29,229 (20.0) 27,534 (20.1) 912 (18.0) 126 (18.1) 657 (17.6) 
Missing 4544 4,186 184 36 138 
Dietary Vitamin D 
(mcg/d) 
     
Mean (SD) 4.4 (3.0) 4.4 (3.0) 4.3 (3.1) 4.3 (3.2) 4.3 (3.1) 
<2.1 29,229 (20.0) 27,169 (19.9) 1,110 (21.9) 139 (19.9) 811 (21.8) 
2.1-3.1 29,229 (20.0) 27,252 (19.9) 1,064 (21.0) 159 (22.8) 754 (20.2) 
3.1-4.3 29,229 (20.0) 27,347 (20.0) 991 (19.5) 145 (20.8) 746 (20.0) 
4.3-6.2 29,229 (20.0) 27,408 (20.1) 960 (18.9) 123 (17.6) 738 (19.8) 
>6.2 29,229 (20.0) 27,471 (20.1) 950 (18.7) 132 (18.9) 676 (18.1) 
Missing 4544 4,186 184 36 138 
Supplemental Calcium      
Au
tho
r M
an
us
cri
pt
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
(mg/d) 
Mean (SD)  360.7 (574.3) 364.9 (555.9) 279.5 (476.7) 232.4 (416.2) 341.5 (1115.0) 
0 65,456 (43.4) 60,538 (43.0) 2,613 (49.7) 401 (54.6) 1,904 (49.3) 
<1200  73,121 (48.5) 68,811 (48.9) 2,340 (44.5) 300 (40.9) 1,670 (43.2) 
≥1200  12,111 (8.0) 11,483 (8.2) 306 (5.8) 33 (4.5) 289 (7.5) 
Missing 1 1 0 0 0 
Supplemental Vitamin D 
(IU/d) 
     
Mean (SD) 199.4 (247.9) 200.8 (248.2) 180.2 (243.4) 158.6 (214.3) 180.8 (248.8) 
0 77,248 (51.3) 71,733 (50.9) 2,909 (55.3) 431 (58.7) 2,175 (56.3) 
<600  64,172 (42.6) 60,321 (42.8) 2,107 (40.1) 279 (38.0) 1,465 (37.9) 
≥600  9,268 (6.2) 8,778 (6.2) 243 (4.6) 24 (3.3) 223 (5.8) 
Missing 1 1 0 0 0 
Diabetes treated       
No 143,875 (95.6) 134,746 (95.8) 4,884 (93.0) 667 (90.9) 3,578 (92.7) 
Yes 6,675 (4.4) 5,958 (4.2) 370 (7.0) 67 (9.1) 280 (7.3) 
Au
tho
r M
an
us
cri
pt
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Missing 139 129 5 0 5 
Age at menopause      
Mean (SD) 48.1 (6.4) 48.1 (6.4) 47.3 (6.9) 46.4 (7.5) 47.5 (6.8) 
Missing 6,106 5,645 235 41 185 
Menopausal hormone 
therapy 
     
Never used 65,610 (43.6) 61,242 (43.5) 2,250 (42.8) 333 (45.4) 1,785 (46.2) 
Past user 23,952 (15.9) 22,299 (15.8) 891 (17.0) 121 (16.5) 641 (16.6) 
Current user 60,995 (40.5) 57,170 (40.6) 2,111 (40.2) 280 (38.1) 1,434 (37.2) 
Missing 132 122 7 0 3 
Total MET hours/week      
Mean (SD) 12.5 (13.7) 12.6 (13.8) 11.2 (13.0) 10.1 (12.6) 11.0 (13.3) 
None 23,632 (15.7) 21,817 (15.5) 932 (17.8) 154 (21.0) 729 (18.9) 
<5 31,598 (21.0) 29,267 (20.8) 1,239 (23.6) 181 (24.7) 911 (23.6) 
5-<10 26,043 (17.3) 24,315 (17.3) 885 (16.9) 141 (19.3) 702 (18.2) 
10-<30 53,729 (35.7) 50,605 (36.0) 1,755 (33.5) 202 (27.6) 1,167 (30.3) 
Au
tho
r M
an
us
cri
pt
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
≥30 15,312 (10.2) 14,480 (10.3) 434 (8.3) 54 (7.4) 344 (8.9) 
Missing 375 349 14 2 10 
Bisphosphonates      
No 147,593 (97.9) 137,933 (97.9) 5,143 (97.8) 719 (98.0) 3,798 (98.3) 
Yes 3,094 (2.1) 2,898 (2.1) 116 (2.2) 15 (2.0) 65 (1.7) 
Missing 2 2 0 0 0 
Selective Estrogen 
Receptor Modulators 
     
No 150,646 
(99.97) 
140,792 
(99.97) 
5,259 (100.0) 733 (99.86) 3,862 (99.97) 
Yes 41 (0.03) 39 (0.03) 0 (0.0) 1 (0.14) 1 (0.03) 
Missing 2 2 0 0 0 
Calcitonin      
No 150,216 (99.7) 140,401 (99.7) 5,237 (99.6) 732 (99.7) 3,846 (99.6) 
Yes 471 (0.3) 430 (0.3) 22 (0.4) 2 (0.3) 17 (0.4) 
Missing 2 2 0 0 0 
Au
tho
r M
an
us
cri
pt
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Oral Corticosteroids       
No 149,610 (99.3) 139,868 (99.3) 5,210 (99.1) 725 (98.8) 3,807 (98.6) 
Yes 1,077 (0.7) 963 (0.7) 49 (0.9) 9 (1.2) 56 (1.4) 
Missing 2 2 0 0 0 
Anti-epileptics      
No 149,135 (99.0) 139,419 (99.0) 5,184 (98.6) 722 (98.4) 3,810 (98.6) 
Yes 1,552 (1.0) 1,412 (1.0) 75 (1.4) 12 (1.6) 53 (1.4) 
Missing 2 2 0 0 0 
Proton Pump inhibitors      
No 147,422 (97.8) 137,872 (97.9) 5,079 (96.6) 712 (97.0) 3,759 (97.3) 
Yes 3,265 (2.2) 2,959 (2.1) 180 (3.4) 22 (3.0) 104 (2.7) 
Missing 2 2 0 0 0 
Thiazolidinediones      
No 150,554 (99.9) 140,725 (99.9) 5,246 (99.8) 732 (99.7) 3,851 (99.7) 
Yes 133 (0.1) 106 (0.1) 13 (0.2) 2 (0.3) 12 (0.3) 
Missing 2 2 0 0 0 
Au
tho
r M
an
us
cri
pt
  Urinary Tract Stone Status* 
 Total No Baseline only 
Recurrent 
(baseline and 
incident) 
Incident only 
(not at 
baseline) 
 150,689 140,833 5,259 734 3,863 
Characteristic N (%) N (%) N (%) N (%) N (%) 
Thiazides      
No 134,762 (89.4) 126,071 (89.5) 4,647 (88.4) 648 (88.3) 3,396 (87.9) 
Yes 15,925 (10.6) 14,760 (10.5) 612 (11.6) 86 (11.7) 467 (12.1) 
Missing 2 2 0 0 0 
Loop Diuretics      
No 146,999 (97.6) 137,514 (97.6) 5,081 (96.6) 708 (96.5) 3,696 (95.7) 
Yes 3,688 (2.4) 3,317 (2.4) 178 (3.4) 26 (3.5) 167 (4.3) 
Missing 2 2 0 0 0 
Thyroid       
No 129,819 (86.2) 121,359 (86.2) 4,515 (85.9) 642 (87.5) 3,303 (85.5) 
Yes 20,868 (13.8) 19,472 (13.8) 744 (14.1) 92 (12.5) 560 (14.5) 
Missing 2 2 0 0 0 
Allopurinol      
No 150,141 (99.6) 140,388 (99.7) 5,186 (98.6) 724 (98.6) 3,843 (99.5) 
Yes 546 (0.4) 443 (0.3) 73 (1.4) 10 (1.4) 20 (0.5) 
Missing 2 2 0 0 0 
Au
tho
r M
an
us
cri
pt
*Categories are mutually exclusive. 
 
 
1Values are expressed as N (%) unless otherwise noted. 
 
 
2Those <55 years old at baseline are represented in separate category, fracture age 55+ is not applicable for this group. 
 
 
 
 
 
